1. Global tuberculosis report. Geneva: World Health Organization; 2020 (, accessed 3 March 2022).
  2. The end TB strategy. Geneva: World Health Organization; 2015 (, accessed 3 March 2022).
  3. Guidelines for treatment of drug-susceptible tuberculosis and patient care. Geneva: World Health rganization; 2017 (, accessed 3 March 2022).
  4. Treatment of tuberculosis, guidelines for national programmes, fourth edition. Geneva: World Health Organization; 2010 (, accessed 3 March 2022).
  5. Fox W, Ellard GA, Mitchison DA. Studies on the treatment of tuberculosis undertaken by the British Medical Research Council tuberculosis units, 1946–1986, with relevant subsequent publications. Int J Tuberc Lung Dis. 1999;3(10 Suppl 2):S231–79.
  6. WHO handbook for guideline development. Geneva: World Health Organization; 2014:167 (, accessed 3 March 2022).
  7. About the WHO Guidelines Review Committee. Geneva: World Health Organization; 2021 (, accessed 3 March 2022).
  8. Guyatt GH, Oxman AD, Gunn EV, Kunz R, Falck-Ytter Y, Alonso-Coello P et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336(7650):924–6.
  9. Menzies D, Benedetti A, Paydar A, Martin I, Royce S, Pal M et al. Effect of duration and intermittency of rifampin on tuberculosis treatment outcomes: a systematic review and meta-analysis. PLoS Med. 2009;6(9):e1000146. doi: 10.1371/journal.pmed.1000146.
  10. Updated recommendations on HIV prevention, infant diagnosis, antiretroviral initiation and monitoring. Geneva: World Health Organization; 2021 (, accessed 3 March 2022).
  11. Menzies D, Benedetti A, Paydar A, Royce S, Pal M, Burman W et al. Standardized treatment of active tuberculosis in patients with previous treatment and/or with mono-resistance to isoniazid: a systematic review and meta-analysis. PLoS Med. 2009;6(9):e1000150. doi:10.1371/journal.pmed.1000150.
  12. Jindani A, Nunn AJ, Enarson DA. Two 8-month regimens of chemotherapy for treatment of newly diagnosed pulmonary tuberculosis: international multicentre randomised trial. Lancet. 2004;364(9441):1244–51.
  13. Gillespie SH, Crook AM, McHugh TD, Mendel CM, Meredith SK et al. Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis. N Engl J Med. 2014;371(17):1577–87. doi:10.1056/NEJMoa1407426.
  14. Merle CS, Fielding K, Bah Sow O, Gninafon N, Lo MB, Mthiyane T et al. A four-month gatifloxacin-containing regimen for treating tuberculosis. N Engl J Med. 2014;371(17):1588–98. doi:10.1056/NEJMoa1315817.
  15. Blanc FX, Sok T, Laureillard D, Borand L, Rekacewicz C, Nerrienet E et al. Earlier versus later start of antiretroviral therapy in HIV-infected adults with tuberculosis. N Engl J Med. 2011;365(16):1471–81. doi:10.1056/NEJMoa1013911.
  16. Johnson JL, Hadad DJ, Dietze R, Noia Maciel EL, Sewali B, Gitta P et al. Shortening treatment in adults with noncavitary tuberculosis and 2-month culture conversion. Am J Respir Crit Care Med. 2009;180(6):558–63.
  17. Lienhardt C, Cook SV, Burgos M, Yorke-Edwards V, Rigouts L, Anyo G et al. Efficacy and safety of a 4-drug fixed-dose combination regimen compared with separate drugs for treatment of pulmonary tuberculosis: the Study C randomized controlled trial. JAMA. 2011;305(14):1415–23. doi:10.1001/jama.2011.436.
  18. Swaminathan S, Narendran G, Venkatesan P, Iliayas S, Santhanakrishnan R, Aravindan Menon P et al. Efficacy of a 6-month versus 9-month intermittent treatment regimen in HIV-infected patients with tuberculosis: a randomized clinical trial. Am J Respir Crit Care Med. 2010;181(7):743–51. doi:10.1164/rccm.200903–0439OC. 
  19. Guidance for national tuberculosis programmes on the management of tuberculosis in children. Geneva: World Health Organization; 2014 (, accessed 3 March 2022).
  20. Albanna AS, Smith BM, Cowan D, Menzies D. Fixed-dose combination antituberculosis therapy: a systematic review and meta-analysis. Eur Respir J. 2013;42(3):721–32. doi:10.1183/09031936.00180612.
  21. Gallardo CR, Comas DR, Valderrama Rodríguez A, Roqué i Figuls M, Parker LA, Caylà J et al. Fixed-dose combinations of drugs versus single-drug formulations for treating pulmonary tuberculosis. Cochrane Database Syst Rev. 2016(5):CD009913. doi:10.1002/14651858.CD009913.pub2.
  22. Blomberg B, Spinaci S, Fourie B, Laing R. The rationale for recommending fixed-dose combination tablets for treatment of tuberculosis. Bull World Health Organ. 2001;79(1):61–8 (, accessed 3 March 2022).
  23. Milan-Segovia RC, Domínguez-Ramírez AM, Jung-Cook H, Magaña-Aquino M, Romero-Méndez MC, Medellín-Garibay SE et al. Relative bioavailability of rifampicin in a three-drug fixed-dose combination formulation. Int J Tuberc Lung Dis. 2010;14(11):1454–60.
  24. Hao L-H, Guo S-C, Liu C-C, Zhu H, Wang B, Fu L et al. Comparative bioavailability of rifampicin and isoniazid in fixed-dose combinations and single-drug formulations. Int J Tuberc Lung Dis. 2014;18(12):1505–12. doi:10.5588/ijtld.13.0647.
  25. Aung KJM, Declercq E, Ali MdA, Naha S, Datta Roy SC, Taled NMdA et al. Extension of the intensive phase reduces relapse but not failure in a regimen with rifampicin throughout. Int J Tuberc Lung Dis. 2012;16(4):455–61. doi:10.5588/ijtld.11.0216.
  26. Jindani A, Harrison TS, Nunn AJ, Phillips PJ, Churchyard GJ, Charalambous S et al. High-dose rifapentine with moxifloxacin for pulmonary tuberculosis. N Engl J Med. 2014;371(17):1599–608. doi:10.1056/ NEJMoa1314210.
  27. Dorman SE, Nahid P, Kurbatova EB, Phillips PJ, Bryant K, Dooley KE et al. Four-month rifapentine regimens with or without moxifloxacin for tuberculosis. N Engl J Med. 2021;384(18):1705–18. doi:10.1056/NEJMoa2033400. 
  28. Ismail NA, Mvusi L, Nanoo A, Dreyer A, Omar SV, Babatunde S et al. Prevalence of drug-resistant tuberculosis and imputed burden in South Africa: a national and sub-national cross-sectional survey. Lancet Infect Dis. 2018;18(7):779–87. doi:10.1016/S1473–3099(18)30222–6. 
  29. Kayomo MK, Mbula VN, Aloni M, André E, Riogouts L, Boutachkourt F et al. Targeted next-generation sequencing of sputum for diagnosis of drug-resistant TB: results of a national survey in Democratic Republic of the Congo. Sci Rep. 2020;10(1):10786.
  30. Lim DR, Dean AS, Taguinod-Santiago MR, Borbe-Reyes A, Cabibbe AM, Zignol M et al. Low prevalence of fluoroquinolone resistance among patients with tuberculosis in the Philippines: results of a national survey. Eur Respir J. 2018;51(3). doi:10.1183/13993003.02571–2017.
  31. Mesfin AB, Araia ZZ, Beyene HN, Mebrahtu AH, Suud NN, Berhane YM et al. First molecular-based anti-TB drug resistance survey in Eritrea. Int J Tuberc Lung Dis. 2021;25(1):43–51. doi:10.5588/ijtld.20.0558.
  32. Zignol M, Dean AS, Alikhanova N, Andres S, Cabibbe AM, Cirillo DM et al. Population-based resistance of Mycobacterium tuberculosis isolates to pyrazinamide and fluoroquinolones: results from a multicountry surveillance project. Lancet Infect Dis. 2016;16(10):1185–92. doi:10.1016/S1473–3099(16)30190–6.
  33. Zvada SP, Van Der Walt J-S, Smith PJ, Fourie PB, Roscigno G, Mitchison D et al. Effects of four different meal types on the population pharmacokinetics of single-dose rifapentine in healthy male volunteers. Antimicrob Agents Chemother. 2010;54(8):3390–4. doi:10.1128/AAC.00345–10.
  34. Turkova, A., et al., Shorter treatment for non-severe tuberculosis in African and Indian children. N. Engl. J. Med, 2022. 
  35. Chabala, C., et al., Shorter treatment for minimal tuberculosis (TB) in children (SHINE): a study protocol for a randomised controlled trial. Trials, 2018. 19(1): p. 1–12.
  36. WHO case definitions of HIV for surveillance and revised clinical staging and immunological classification of HIV-related disease in adults and children. Geneva: World Health Organization; 2007 (, accessed 3 March 2022).
  37. Guideline: updates on the management of severe acute malnutrition in infants and children. Geneva: World Health Organization; 2013 (, accessed 3 March 2022).
  38. WHO operational handbook on tuberculosis. Module 4: Treatment – Drug-resistant tuberculosis treatment.Geneva: World Health Organization; 2020 (,accessed 3 March 2022).
  39. WHO consolidated guidelines on tuberculosis. Module 1: Prevention – tuberculosis preventive treatment. Geneva: World Health Organization; 2020 (,accessed 3 March 2022).
  40. Khan FA, Minion J, Pai M, Rovce S, Burman W, Harries AD et al. Treatment of active tuberculosis in HIV-coinfected patients: a systematic review and meta-analysis. Clin Infect Dis. 2010;50(9):1288–99. doi:10.1086/651686.
  41. Consolidated guidelines on HIV prevention, testing, treatment, service delivery and monitoring: recommendations for a public health approach. Geneva: World Health Organization; 2021 (, accessed 3 March 2022).
  42. Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach – 2010 revision. Geneva: World Health Organization; 2010 (, accessed 3 March 2022).
  43. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection:recommendations for a public health approach. Geneva: World Health Organization; 2016 (, accessed 3 March 2022).
  44. Guidelines for managing advanced HIV disease and rapid initiation of antiretroviral therapy. Geneva: World Health Organization; 2017 (, accessed 3 March 2022).
  45. Chotmongkol V, Jitpimolmard S, Thavornpitak Y. Corticosteroid in tuberculous meningitis. J Med Assoc Thai. 1996;79(2):83–90.
  46. Kumarvelu S, Prasad K, Khosla A, Behari M, Ahuja GK. Randomized controlled trial of dexamethasone in tuberculous meningitis. Tuber Lung Dis. 1994;75(3):203–7. doi:10.1016/0962–8479(94)90009–4.
  47. Malhotra HS, Garg RK, Singh MK, Agarwal A, Verma R. Corticosteroids (dexamethasone versus intravenous methylprednisolone) in patients with tuberculous meningitis. Ann Trop Med Parasitol. 2009;103(7):625–34. doi:10.1179/000349809X12502035776315.
  48. Schoeman JF, Van Zyl LE, Laubscher JA, Donald PR. Effect of corticosteroids on intracranial pressure, computed tomographic findings, and clinical outcome in young children with tuberculous meningitis. Pediatrics. 1997;99(2):226–31. doi:10.1542/peds.99.2.226.
  49. Thwaites GE, Nguyen DB, Nguyen HD, Hoang TQ, Do TTO, Nguyen TCT et al. Dexamethasone for the treatment of tuberculous meningitis in adolescents and adults. N Engl J Med. 2004;351(17):1741–51. doi:10.1056/NEJMoa040573.
  50. Mayosi BM, Ntsekhe M, Volmink JA, Commerford PJ. Interventions for treating tuberculous pericarditis. Cochrane Database Syst Rev. 2002(4):CD000526. doi:10.1002/14651858.CD000526. 
  51. Critchley JA, Young F, Orton L, Garner P. Corticosteroids for prevention of mortality in people with tuberculosis: a systematic review and meta-analysis. Lancet Infect Dis. 2013;13(3):223–37. doi:10.1016/S1473–3099(12)70321–3.
  52. Mayosi BM, Ntsekhe M, Bosch J, Pandie S, Jung H, Gumedze F et al. Prednisolone and Mycobacterium indicus pranii in tuberculous pericarditis. N Engl J Med. 2014;371(12):1121–30. doi:10.1056/NEJMoa1407380.
  53. Hakim JG, Ternouth I, Mushangi E, Siziya S, Robertson V, Malin A. Double blind randomised placebo controlled trial of adjunctive prednisolone in the treatment of effusive tuberculous pericarditis in HIV seropositive patients. Heart. 2000;84(2):183–8. doi:10.1136/heart.84.2.183.
  54. Reuter H, Burgess LJ, Louw VJ, Doubell AF. Experience with adjunctive corticosteroids in managing tuberculous pericarditis. Cardiovasc J S Afr. 2006;17(5):233–8.
  55. Schrire V. Experience with pericarditis at Groote Schuur Hospital, Cape Town: an analysis of one hundred and sixty cases studied over a six-year period. S Afr Med J. 1959;33:810–7.
  56. Strang JI, Kakaza HH, Gibson DG, Allen BW, Mitchison DA, Evans DJ et al. Controlled clinical trial of complete open surgical drainage and of prednisolone in treatment of tuberculous pericardial effusion in Transkei. Lancet. 1988;2(8614):759–64. doi:10.1016/s0140–6736(88)92415–4. 
  57. Strang JI, Kakaza HH, Gibson DG, Girling DJ, Nunn AJ, Fox W et al. Controlled trial of prednisolone as adjuvant in treatment of tuberculous constrictive pericarditis in Transkei. Lancet. 1987;2(8573):1418–22. doi:10.1016/s0140–6736(87)91127–5.

Book navigation